Samsung Bioepis Co., Ltd. recalls HADLIMA (adalimumab-bwwd) injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Lack of Assurance of Sterility.
- Products
-
- HADLIMA (adalimumab-bwwd) injection
- Company
- Samsung Bioepis Co., Ltd.
- Where it was sold
-
Distributed only to one warehouse in NJ. with no further distribution
States: New Jersey
- Units affected
- 5,518 packs (11,036 Syringes) 2 syringes/carton)
- About this recall
- HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.